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LevetiracetamWe evaluated nonpsychotic behavioral adverse events (BAEs) in patients receiving levetiracetam (LEV) who
switched to brivaracetam (BRV). Patients ≥16 years of age, receiving 2–3 antiepileptic drugs (AEDs), including
LEV 1–3 g/day, and experiencing BAEs within 16 weeks of LEV treatment initiation, enrolled in an open-label
Phase 3b study (NCT01653262) comprising a ≤1-week screening period, an immediate switch from LEV to
BRV 200 mg/day (without titration), and a 12-week treatment period. The percentages of patients with
investigator-assessed clinically meaningful reduction in BAEs, shift in maximum BAE intensity, and change in
health-related quality of life (HRQoL) (Patient-Weighted Quality of Life in Epilepsy Inventory—Form 31
[QOLIE-31-P]) were assessed. Of 29 patients enrolled, 26 (89.7%) completed the study. At the end of the treat-
ment period, 27/29 (93.1%) patients switched to BRV had clinicallymeaningful reductions in BAEs. Physicians re-
ported a reduction in the maximum intensity of primary BAEs in 27/29 (93.1%) patients. Mean change from
baseline toWeek 12 in QOLIE-31-P total score was 12.1, indicating improved HRQoL. During the treatment peri-
od, 23/29 (79.3%) patients reported treatment-emergent adverse events (TEAEs). One patient reported a serious
TEAE (suicidal ideation and suicide attempt). Two patients discontinued BRV because of TEAEs. Findings from
this small study suggest that patients experiencing BAEs associatedwith LEVmay beneﬁt from switching to BRV.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug tolerability is a signiﬁcant limiting factor in the treatment of pa-
tients with epilepsy, and long-term retention rates are often determined
by adverse event proﬁles [1]. Levetiracetam (LEV) treatment has been re-
ported to be associated with nonpsychotic behavioral adverse events
(BAEs; classiﬁed by the Medical Dictionary for Regulatory Activities,
e.g., agitation, antisocial reaction, anxiety, apathy, depersonalization, de-
pression, emotional lability, euphoria, hostility, nervousness, neurosis,
and personality disorder) in patients with epilepsy [2]. Previous analyses
of LEV pivotal studies showed that ~13% of adult patients treated with
LEV reported behavioral symptoms compared with ~6% of those who re-
ceived placebo [3,4]. However, it has been suggested that patients taking
LEV in clinical practice experience more behavioral symptoms than re-
ported in clinical trials. In a study evaluating retention rates of newerporate Drive Suite 100, Raleigh,
71.
. This is an open access article underantiepileptic drugs (AEDs), 105/196 (53.6%) patients continued to take
LEV adjunctive therapy after 2 years, while 91 (46.4%) had discontinued
therapy [1]. BAEs accounted for 40.4% of the reasons for discontinuation
(N = 94). Other leading causes of discontinuation were sedation
(24.5%) and ineffectiveness (23.4%) [1]. Similar results were observed in
elderly patients with newly diagnosed epilepsy; the retention rate for
LEV monotherapy was 61.5%, and BAEs were reported in 29/122
(23.8%) patients [5].
Brivaracetam (BRV) is a selective, high-afﬁnity ligand of the synaptic
vesicle protein 2A (SV2A); it has a binding afﬁnity approximately 15- to
30-fold higher than LEV [6], another SV2A ligand. In addition to this
higher afﬁnity for the SV2A binding site, BRV also differs from LEV in
that it does not show modulatory activity at α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors [7], whereas LEV
does [8], suggesting that BRV has a distinct pharmacological proﬁle
compared with LEV. In Phase 3 clinical trials, BRV (50–200 mg/day)
has demonstrated efﬁcacy and a good tolerability proﬁle in patients
with partial-onset seizures (POS) [9–12].
The primary objective of this study was to evaluate potential changes
in BAEs among patients who switched to BRV, without titration, afterthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sidered by the investigators to be related to LEV.
2. Materials and methods
2.1. Study design
This was a Phase 3b, open-label, single-arm, prospective,
multicenter study (N01395; NCT01653262) conducted between July
2012 and November 2013. Patients were enrolled from North America
(USA) and Europe (France, Germany, and Spain).
The study comprised a screening period of ≤1 week, a retrospective
baseline period during LEV treatment where seizure counts were
recorded for 4 weeks and BAEs for up to 16 weeks before switching to
BRV, and a treatment period of 12 weeks. On Day 1 of the treatment
period, the last dose of LEV was taken in the morning, and patients re-
ceived theﬁrst dose of BRV100mgb.i.d. (200mg/day)without titration
in the evening. Dose adjustments within the range of 50–200 mg/day
were allowed if necessary. Completers were down-titrated over a max-
imum of 4 weeks followed by a 2- to 3-week study-drug-free period or
entered into a long-term follow-up study without down-titration
(N01372; NCT01728077).
The study was conducted in accordance with the International
Conference onHarmonization notes for Guidance onGood Clinical Prac-
tice and theDeclaration of Helsinki. The study protocolwas approved by
institutional review boards at all study sites, and written informed
consent was obtained from all patients or their legal representatives
before enrolment.
2.2. Study population
Patients recruited were adults ≥16 years old, with well-characterized
POS or primary generalized epilepsy [13]. Patients, receiving LEV in
clinical practice at a recommended therapeutic dose (1–3 g/day), could
participate if the investigator expected that they would have beneﬁtted
or were beneﬁtting from LEV, but discontinuation of LEV was warranted
within 16 weeks of initiation because of BAEs. Patients must have been
receiving 2–3 AEDs, including LEV at a dosage that had been stable for
≥4 weeks (≥12 weeks for phenobarbital, phenytoin, and primidone)
prior to screening.
Women without childbearing potential (postmenopausal or
surgically sterilized) were eligible to participate. Women of childbear-
ing potential were eligible with the use of a medically accepted
contraceptive method. A family member/caregiver or close contact
person, knowledgeable on a daily basis of the patient's adverse events,
was required to be available during all study visits.
Key exclusion criteria included experience of cluster orﬂurry seizures,
a history or presence of psychogenic nonepileptic seizures, or status
epilepticus during the year preceding the study. Patients receiving LEV
at a recommended therapeutic dose (1–3 g/day) for N16 weeks were
not eligible for this study. Other exclusion criteria included rapidly
progressing brain disorder, brain tumor, or other serious uncontrolled
disease.
2.3. Assessments
The primary safety variable was the proportion of patients achieving
a clinically meaningful reduction in BAEs at the end of the treatment
period, based on the investigator's overall assessment. Investigators an-
swered ‘yes’ or ‘no’ to the following question: “Has there been a clinical-
ly meaningful reduction of nonpsychotic behavioral side effects since
the start of BRV?”. Secondary safety variables included investigator-
assessed shift in maximum intensity (‘resolved’, ‘mild’, ‘moderate’, or
‘severe’) of primary BAEs (i.e., the BAE[s] associated with discontinua-
tion of LEV) over the treatment period, Investigator Global Evaluation
of Behavioral Side Effects (I-GEBSE; a 7-point scale ranging from‘marked worsening’ to ‘marked improvement’), complete abatement
of primary BAEs based on investigator assessment, freedom from
BAEs, treatment-emergent adverse events (TEAEs), withdrawal due to
an adverse event, and occurrence of serious adverse events. Patients
were asked at each study visit whether they had experienced any
adverse events, and they could also spontaneously report adverse
events. Other safety evaluationswere collection of blood and urine sam-
ples for routine laboratory investigations, monitoring of electrocardio-
grams, vital signs, and physical and neurologic examinations.
Secondary efﬁcacy variables included POS frequency during the
treatment period, seizure days during the treatment period for patients
with idiopathic generalized epilepsy, seizure freedom (all seizure
types), change in health-related quality of life (HRQoL) assessed using
Patient-Weighted Quality of Life in Epilepsy Inventory—Form 31
(QOLIE-31-P), Patient Global Evaluation Scale (P-GES), and Investigator
Global Evaluation Scale (I-GES). Baseline seizures were collected retro-
spectively and, thereafter, were recorded on the patient's daily record
card. A speciﬁc effect of BRV on the occurrence of generalized seizures
was not assessed.
2.4. Analysis
As thiswas an exploratory study, therewas no sample size calculation,
and all analyses were descriptive. The aim was to recruit 30 patients.
Analyses of the safety and efﬁcacy variables were based on the ﬁnal
data available for each patient (last observation carried forward).
3. Results
Because of unexpected recruitment difﬁculties, enrollment was
closed at 29 patients. This decision was not made because of any safety
or compliance concerns. The slightly lower sample size was considered
as insigniﬁcant and not expected to affect the planned analyses. Of the
29 patients enrolled, 26 (89.7%) patients completed the study. During
the treatment period, 7/29 (24.1%) patients required a dose adjustment.
Reasons for discontinuation were: TEAEs (2/29 [6.9%]) and lack of efﬁ-
cacy (1/29 [3.4%]). The mean (standard deviation [SD]) age was 35.8
(11.8) years (range: 19–55 years); 15 (51.7%) were male, and 24
(82.8%) were Caucasian. Baseline demographics and disease character-
istics are reported in Table 1. The primary BAEs that led to discontinua-
tion of LEV treatment inmore than one patient were (preferred term, in
order of frequency) irritability, anxiety, anger (including verbatim term
short temper), agitation, depression, mood swings, aggression, fatigue,
and insomnia.
3.1. Safety
Themajority of patients (n= 27 [93.1%]) who switched from LEV to
BRV had a clinicallymeaningful reduction in BAEs, as determined by the
investigator, at the end of the treatment period. The secondary safety
analyses also showed improvements in BAEs. A reduction in the
maximum intensity of primary BAEs associated with discontinuation
of LEV was seen in 27/29 (93.1%) patients, and no patients reported a
worsened intensity from baseline to the end of the treatment period
(Table 2).
A total of 20/29 (69.0%) patients showed a marked or moderate
improvement in BAEs, measured by the I-GEBSE. There was a slight
improvement of BAEs in 4/29 patients. One patient (3.4%) had
slight worsening, and one patient (3.4%) had marked worsening of
BAEs. I-GEBSE data were missing for one patient (3.4%).
At the end of the treatment period, complete abatement (events
which ended during the treatment period) from primary BAEs was re-
ported for 18 (62.1%) patients. Of these, three (10.3%) had freedom
fromBAEs throughout the treatment period. Themedian time to prima-
ry BAE resolution (deﬁned as the time between the date of the ﬁrst dose
Table 1
Baseline demographics and disease characteristics.
Characteristic Brivaracetam
(N = 29)
Age, mean (SD) 35.8 (11.8)
Sex, n (%)
Male 15 (51.7)
Female 14 (48.3)
Weight, mean (kg) 82.3 (23.1)
Height, mean (cm) 172.6 (10.6)
BMI, mean (kg/m2) 27.6 (7.1)
Race, n (%)
White 24 (82.8)
Black 0 (0.0)
Asian 0 (0.0)
Other 1 (3.4)
Missing 4 (13.8)
Ethnicity, n (%)
Hispanic or Latino 3 (10.3)
Not Hispanic or Latino 22 (75.9)
Missing 4 (13.8)
Epilepsy duration (years), mean (SD) 16.2 (12.7)
Epileptic seizure proﬁle, n (%)
Partial-onset seizures 22 (75.9)
Simple partial seizures 10 (34.5)
Complex partial seizures 15 (51.7)
Partial evolving to secondarily generalized seizures 16 (55.2)
Primary generalized seizures 9 (31.0)
Absence 4 (13.8)
Atypical absence 1 (3.4)
Myoclonic 5 (17.2)
Clonic 1 (3.4)
Tonic 0 (0.0)
Tonic–clonic 8 (27.6)
Atonic 1 (3.4)
Unclassiﬁable 1 (3.4)
Concomitant AEDs in ≥10% of the patient population, n (%)
Lamotrigine 11 (37.9)
Topiramate 4 (13.8)
Carbamazepine 3 (10.3)
Lacosamide 3 (10.3)
Oxcarbazepine 3 (10.3)
Valproate 3 (10.3)
Clobazam 3 (10.3)
Table 3
Overall summary of treatment-emergent adverse events reported during the treatment
period.
Number of patients (%)
N = 29
Any TEAEs 23 (79.3)
Drug-related TEAEs 10 (34.5)
Severe TEAEs 3 (10.3)
Discontinuation due to TEAEs 2 (6.9)
Serious TEAEs 1 (3.4)
Deaths 0 (0)
TEAEs with reported frequency N5%
Headache 5 (17.2)
Fatigue 3 (10.3)
Back pain 3 (10.3)
Depression 2 (6.9)
Dizziness 2 (6.9)
Insomnia 2 (6.9)
Nasopharyngitis 2 (6.9)
Tremor 2 (6.9)
TEAE, treatment-emergent adverse event.
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ﬁrst BRV dosage.
Non-behavioral TEAEs were reported in 23/29 (79.3%) patients; the
most frequently reported TEAEs were headache (17.2%), fatigue
(10.3%), and back pain (10.3%) (Table 3). The majority of TEAEs were
mild or moderate in intensity. TEAEs leading to discontinuation of the
study drug occurred in two (6.9%) patients; one case of myoclonic
epilepsy was considered treatment-related, and one patient, with a
history of altered moods andmorbid thoughts that had been attributed
to LEV treatment, reported a serious TEAE (suicidal ideation and suicide
attempt) which was not considered related to the study drug. One
patient discontinued treatment because of lack of efﬁcacy.Table 2
Shift inmaximum intensity of nonpsychotic behavioral adverse events primarily associat-
ed with discontinuation of levetiracetam over the treatment period.
Intensity of BAEs at baseline Intensity of BAEs at end of treatment period, n (%)
Resolved Mild Moderate Severe
Mild 1 (3.4) 1 (3.4) 0 0
Moderate 10 (34.5) 3 (10.3) 1 (3.4) 0
Severe 8 (27.6) 2 (6.9) 3 (10.3) 0
Total 19 (65.5) 6 (20.7) 4 (13.8) 0
BAE, nonpsychotic behavioral adverse event.3.2. Efﬁcacy
Themediannumber of POSduring the treatment periodwas similar to
baseline during LEV treatment (median increase of 0.6 seizures/28 days).
Seizure freedom (all seizure types) during the treatment period was ob-
served in 7/29 (24.1%) patients. A speciﬁc effect of BRV on the occurrence
of generalized seizures was not assessed.
Administration of BRV resulted in improved HRQoL as indicated by a
mean (SD) increase of 12.1 (11.4) from baseline to the end of the
treatment period in QOLIE-31-P total score. There was a consistent
mean (SD) improvement in all QOLIE-31-P subscale scores from base-
line to the end of the treatment period: cognitive functioning 10.4
(19.0), emotional well-being 14.0 (17.4), energy/fatigue 10.6 (13.7),
medication effects 27.6 (25.5), overall quality of life 13.8 (13.3), seizure
worry 12.1 (26.0), social functioning 10.3 (23.3), and health status 6.5
(16.5).
Improvements in P-GES and I-GES atWeek 12were observed for the
majority of patients; the level of improvement as reported by patients
and investigators was similar. For the P-GES, 20/26 (76.9%) patients re-
ported an improvement, and 1/26 (3.8%) reported worsening. Based on
the I-GES, 24/26 (92.3%) investigators reported improvement, and 1/26
(3.8%) reported worsening.4. Discussion
Amarked number of patients experienced a clinicallymeaningful re-
duction in BAEs which, when combined with the observed increase in
QOLIE-31-P scores and the improvements reported in both the P-GES
and I-GES assessments, suggests that a switch from LEV to BRV may
have a positive impact on patients' behavioral proﬁle, quality of life,
and health status. It should be noted that this study recruited patients
for whom the investigator had already decided to discontinue LEV be-
cause of the occurrence of drug-limiting BAEs.
Improvements in QOLIE-31-P were substantial in comparison with
other ﬁxed-dose [14,15] and long-term extension [16,17] studies of
adjunctive AEDs. Those aspects of quality of life associatedwithmedica-
tion effects were particularly improved, which is likely to be related to
the reduction of BAE incidence. The large improvements observed in
QOLIE-31-P may be due to the open-label nature of the study and the
ﬂexible dose design which allowed for adjustments to optimize
tolerability and response.
During treatment with BRV, POS frequency was comparable to the
retrospective baseline. BRV appeared to be well tolerated, and discon-
tinuations due to TEAEs were low (2/29 [6.9%]), which is consistent
with a previous large ﬂexible dose study [11].
168 S.L. Yates et al. / Epilepsy & Behavior 52 (2015) 165–168Overall, results from this small study suggest that patients who ex-
perience BAEs warranting the discontinuation of LEV treatment might
beneﬁt from a switch to BRV without titration. However, results should
be interpreted with caution owing to the small sample size, lack of pro-
spective baseline seizure data, short treatment period, and open-label
design. Therefore, further conﬁrmation of these results in future ran-
domized, blinded studies would be of interest.
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